Clinical trialObsRecruiting
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Recruiting
- Study type
- Observational
- Start
- 6 October 2016
- Expected end
- December 2028
- Enrollment
- 190 participants
- Sites
- 4
- Primary outcomes
- Number of days between biopsy and return of comprehensive genomic results.
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 23
- Registry-listed results paperNRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocar… DOI 10.1158/1078-0432.ccr-19-0191↗
- Builds on itAltered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-19-1543↗
- BackgroundMaintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. DOI 10.1056/nejmoa1903387↗
- BackgroundTemporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Bur… DOI 10.1200/po.18.00057↗
- BackgroundImpact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. DOI 10.1097/coc.0000000000000359↗
- BackgroundNRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. DOI 10.1158/2159-8290.cd-18-0036↗
- BackgroundVirtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. DOI 10.1038/ng.3398↗
- BackgroundMismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. DOI 10.1038/modpathol.2015.89↗
- BackgroundGermline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. DOI 10.1200/jco.2014.59.7401↗
- BackgroundNew targeted therapies in pancreatic cancer. DOI 10.3748/wjg.v21.i20.6127↗
- BackgroundWhole genomes redefine the mutational landscape of pancreatic cancer. DOI 10.1038/nature14169↗
- BackgroundThe current state of pancreatic cancer in Canada: incidence, mortality, and surgical therapy. DOI 10.1097/mpa.0000000000000147↗
- BackgroundOverall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. DOI 10.1038/bjc.2014.418↗
- BackgroundDetection of circulating tumor DNA in early- and late-stage human malignancies. DOI 10.1126/scitranslmed.3007094↗
- BackgroundModified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. DOI 10.1097/mpa.0b013e31829e2006↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes. DOI 10.1038/nature11547↗
- BackgroundATM mutations in patients with hereditary pancreatic cancer. DOI 10.1158/2159-8290.cd-11-0194↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundSubtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. DOI 10.1038/nm.2344↗
- BackgroundFeasibility of identifying pancreatic cancer based on serum metabolomics. DOI 10.1158/1055-9965.epi-10-0712↗
- BackgroundNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). DOI 10.1016/j.ejca.2008.10.026↗
- BackgroundErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III tri… DOI 10.1200/jco.2006.07.9525↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.